Background: Stroke represents a potentially calamitous complication among patients with acute coronary syndrome (ACS) undergoing percutaneous intervention (PCI). Data on the distribution of stroke occurrence post-PCI and its impact on mortality are scarce.
Objectives: We sought to determine the incidence, predictors and impact of stroke on mortality in ACS patients undergoing PCI.
Methods: A total of 19,914 ACS patients underwent PCI in the PROMETHEUS multicenter observational study. We calculated the cumulative stroke incidence at 30 days and 1 year using the Kaplan Meier method. We also compared the distribution of stroke, myocardial infarction (MI), and bleeding across time and evaluated their overlap. Predictors of stroke were identified through multivariable Cox-regression. Stroke, MI, and bleeding were assessed as time-updated covariates to estimate how each impacts subsequent mortality.
Results: We found that 244 patients had a stroke within 1 year, a cumulative incidence of 1.5%. Previous cerebrovascular disease was the strongest predictor for post-PCI stroke, followed by ST-elevation MI presentation, hypertension, non-ST-elevation MI presentation, smoking, female sex, and age. Mortality risk was significantly higher among those who had a stroke versus those who did not (adjusted HR 4.84, p < .0001). However, the association attenuated over time with a much larger effect in the first 30 days of its occurrence (adjusted HR 17.7; 95% CI: 12.3-25.4, p < .0001) versus beyond 30 days (adjusted HR 1.22; 95% CI: 0.6-2.46, p = .58).
Conclusions: Stroke occurrence within 1 year was not uncommon for ACS patients undergoing PCI. When compared with MI and bleeding, stroke had a substantial impact on mortality that attenuated rapidly over time.
Keywords: acute coronary syndrome; percutaneous coronary intervention; stroke.
© 2019 Wiley Periodicals, Inc.
The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry.Catheter Cardiovasc Interv. 2019 Feb 15;93(3):E112-E119. doi: 10.1002/ccd.27860. Epub 2018 Oct 23. Catheter Cardiovasc Interv. 2019. PMID: 30351514 Clinical Trial.
Cardiac troponin after percutaneous coronary intervention and 1-year mortality in non-ST-segment elevation acute coronary syndrome using systematic evaluation of biomarker trends.J Am Coll Cardiol. 2013 Jul 16;62(3):242-251. doi: 10.1016/j.jacc.2013.04.043. Epub 2013 May 15. J Am Coll Cardiol. 2013. PMID: 23684676 Review.
Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.JACC Cardiovasc Interv. 2017 Oct 23;10(20):2017-2025. doi: 10.1016/j.jcin.2017.02.047. Epub 2017 Aug 2. JACC Cardiovasc Interv. 2017. PMID: 28780028 Clinical Trial.
Assessment of the LDL-C/HDL-C ratio as a predictor of one year clinical outcomes in patients with acute coronary syndromes after percutaneous coronary intervention and drug-eluting stent implantation.Lipids Health Dis. 2019 Feb 2;18(1):40. doi: 10.1186/s12944-019-0979-6. Lipids Health Dis. 2019. PMID: 30711009 Free PMC article.
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.Health Technol Assess. 2015 Apr;19(29):1-130. doi: 10.3310/hta19290. Health Technol Assess. 2015. PMID: 25896573 Free PMC article. Review.
- Mahaffey KW, Harrington RA, Simoons ML, et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. the PURSUIT investigators. Circulation. 1999;99(18):2371-2377.
- Genereux P, Bernard S, Palmerini T, et al. Incidence, predictors, and impact of neurological events in non-ST-segment elevation acute coronary syndromes: The ACUITY trial. EuroIntervention. 2014;11(4):399-406.
- Palmerini T, Biondi-Zoccai G, Reggiani LB, et al. Risk of stroke with coronary artery bypass graft surgery compared with percutaneous coronary intervention. J Am Coll Cardiol. 2012;60(9):798-805.
- Giustino G, Redfors B, Kirtane AJ, et al. Platelet reactivity and risk of ischemic stroke after coronary drug-eluting stent implantation: from the ADAPT-DES study. J Am Coll Cardiol Interv. 2018;11(13):1277-1286.
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015.